Back to investors
CATALIO CAPITAL MANAGEMENT, LP
CATALIO CAPITAL MANAGEMENT, LP
Latest filing: 2026-06-30
CATALIO CAPITAL MANAGEMENT, LP runs CATALIO CAPITAL MANAGEMENT, LP and currently holds 39 stock positions, which is fewer than the average of 230 among the investors we track. The portfolio is valued at approximately $532.10M. Their top holdings are AVLN, JNJ, GILD, BBIO, SNDX. The top five represent 34.8% of reported portfolio weight. CATALIO CAPITAL MANAGEMENT, LP ranks #594 out of 1000 investors tracked by Alpha Score. In the most recent quarter, CATALIO CAPITAL MANAGEMENT, LP initiated 8 new positions. They added to 13 existing positions. They trimmed 8 positions. Their current best-performing preview position is DFTX with returns of +148.89%.
Sign in to enable email alerts for this investor.
Showper page
39 stock holdings
| Holding | Weight | Avg Buy | Current | Return | Quarter Change |
|---|---|---|---|---|---|
AV AVLN AVALYN PHARMACEUTICALS INC | 10.37% | $32.92 | $38.37 | +16.56% | New Buy |
 JNJ JOHNSON & JOHNSON | 6.63% | $253.97 | $270.30 | +6.43% | Added +100.00% |
 GILD GILEAD SCIENCES INC | 6.39% | $124.15 | $146.12 | +17.70% | Added +64.31% |
 BBIO BRIDGEBIO PHARMA INC | 6.37% | $74.27 | $81.50 | +9.73% | Added +5.33% |
 SNDX SYNDAX PHARMACEUTICALS INC | 4.99% | $13.20 | $19.65 | +48.86% | Added +16.48% |
 DFTX DEFINIUM THERAPEUTICS INC | 4.97% | $18.90 | $44.91 | +137.62% | Trimmed -45.79% |
 BMY BRISTOL-MYERS SQUIBB CO | 4.47% | $53.94 | $67.02 | +24.24% | Trimmed -1.85% |
AA AADX PARABILIS MEDICINES INC | 4.24% | $22.78 | $14.96 | -34.33% | New Buy |
 NTRA NATERA INC | 4.19% | $184.19 | $332.03 | +80.26% | Added +15.90% |
 INCY INCYTE CORP | 4.08% | $95.08 | $127.81 | +34.42% | Added +5.23% |
Showing 1-10 of 39